Acquisition (Tables)

12 Months Ended

Dec. 31, 2023

Acquisition

Schedule of purchase consideration and allocation of purchase consideration

Cash consideration paid to selling shareholders (i)	$	55,960
Cash consideration paid to settle Zynerba restricted stock awards ("RSAs") as stock options (ii)		4,040
Transaction costs		2,645
Total purchase consideration	$	62,645

(i) The cash consideration paid to selling shareholders was determined based on the total number of Zynerba shares tendered at closing of 50,602,656 at a per share price of $1.1059.

(ii) The cash consideration paid to settle Zynerba restricted stock awards (“RSAs”) and stock options under Zynerba equity incentive plans was determined based on the total number of underlying shares of 4,000,169 at a per share price of $1.1059, less exercise price for the stock options.

Assets acquired
Cash and cash equivalents	$	25,658
Prepaid expenses and other current assets		3,540
Deferred tax asset		44,800
Restricted cash		20
Acquired in-process research and development		2,260
Total assets acquired	$	76,278
Liabilities assumed
Accounts payable		4,995
Accrued expenses and accrued compensation		8,479
Other current liabilities		159
Total liabilities assumed	$	13,633
Net assets acquired	$	62,645